To further validate these findings, we surveyed the expression levels of NLK mRNA in glioma specimens utilizing Oncomine and Rembrandt databases [18, 19] and found that NLK mRNA levels are significantly lower in GBMs compared to non-tumor brain tissues (Figure 1F). The gene discussed is NLK; the disease is central nervous system cancer.